• Merger Hamlet-SelectImmune
  • hamletpharma.com
  • selectimmune.com
    • Årsredovisningar
      • 20/21
      • 21/22
      • 22/23
Hamlet BioPharmaHamlet BioPharma
  • News
    • Press releases
    • Newsletters
    • Media Archive
    • Subscribe
    • Series of digital events
    • Commercial collaborations
  • Drug Development
    • Cancer
    • Infections
    • Tuberculosis
    • Our Pipeline
    • Publications
  • Contact us
  • Hamlet Biopharma
    • Patents
    • Board & Executive Team
  • Finance and Investor Relations
    • Financial Reports
    • Financial Calendar
    • General Meetings
    • The share
    • Spotlight Stock Market
    • Prospectus 2024
Press enter to begin your search
Category

News

Dec 07 2023
Love0

Newsletter – Continuing development of brain tumor therapy

By Hamlet Biopharma News

The brain and spinal cord form the central nervous system, where vital functions are controlled. Brain tumors that disturb those functions may be very destructive…

Read More
Nov 02 2023
Love0

Newsletter – Bladder cancer

By Hamlet Biopharma News
Read More
Oct 16 2023
Love0

Newsletter – Strong anti-tumor effects detected in Alpha1H patients

By Hamlet Biopharma News
Read More
Oct 03 2023
Love0

Newsletter – FDA approval

By Hamlet Biopharma News
Read More

See all news →

Recent Posts

  • Hamlet BioPharma presenterar framgångsrika prekliniska och kliniska data för Alpha1H vid AACR 2025 – stärker positionen inom behandling av blåscancer May 2, 2025
  • Hamlet BioPharma invites to investor meeting on the 23rd of April April 22, 2025
  • New discoveries in infection biology, highlighting the rich potential of non-antibiotic treatments of infections April 8, 2025
  • New scientific advances for Alpha1H highlight the unique discovery pipeline and drug development potential for the treatment of bladder cancer April 8, 2025
  • New granted patents added to Hamlet BioPharma’s extensive patent portfolio in cancer and infection April 7, 2025

hbp-logo

An innovative pharmaceutical company with a broad and strong portfolio of projects for the treatment of cancer and infections.

Hamlet Biopharma AB
Klinikgatan 32
SE-222 42 Lund
info@hamletbiopharma.com
Org. no. 556568-8958

Subscribe to receive newsletters

© 2025 Hamlet BioPharma.

  • News
    • Press releases
    • Newsletters
    • Media Archive
    • Subscribe
    • Series of digital events
    • Commercial collaborations
  • Drug Development
    • Cancer
    • Infections
    • Tuberculosis
    • Our Pipeline
    • Publications
  • Contact us
  • Hamlet Biopharma
    • Patents
    • Board & Executive Team
  • Finance and Investor Relations
    • Financial Reports
    • Financial Calendar
    • General Meetings
    • The share
    • Spotlight Stock Market
    • Prospectus 2024
  • Merger Hamlet-SelectImmune
  • hamletpharma.com
  • selectimmune.com
    • Årsredovisningar
      • 20/21
      • 21/22
      • 22/23

Hamlet Pharma AB

BMC D10
Klinikgatan 32
SE-222 42 Lund, Sweden
+46 40 12 25 00
info@hamletpharma.com

Swedish